iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 28,187 shares were traded during mid-day trading, a decline of 54% from the previous session’s volume of 61,305 shares.The stock last traded at $71.42 and had previously closed at $71.86.
iShares U.S. Pharmaceuticals ETF Stock Performance
The company has a market cap of $716.70 million, a P/E ratio of 6.49 and a beta of 0.58. The business’s 50-day moving average price is $71.18 and its 200 day moving average price is $68.01.
Hedge Funds Weigh In On iShares U.S. Pharmaceuticals ETF
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. McElhenny Sheffield Capital Management LLC bought a new stake in iShares U.S. Pharmaceuticals ETF in the second quarter valued at approximately $18,942,000. Aptus Capital Advisors LLC bought a new stake in iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at $12,165,000. Rockport Wealth LLC bought a new stake in iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at $12,091,000. Concord Investment Counsel Inc. acquired a new stake in iShares U.S. Pharmaceuticals ETF during the 1st quarter valued at $3,880,000. Finally, Southern Capital Advisors LLC lifted its holdings in iShares U.S. Pharmaceuticals ETF by 2.4% during the 2nd quarter. Southern Capital Advisors LLC now owns 39,832 shares of the company’s stock valued at $2,642,000 after purchasing an additional 948 shares during the last quarter.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Further Reading
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- The Significance of Brokerage Rankings in Stock Selection
- Short Sellers Eye Palantir: Should You Buy the Dip?
- Basic Materials Stocks Investing
- Is This NVIDIA Backed Robotics Stock a Buy As It Nears Expansion?
- With Risk Tolerance, One Size Does Not Fit All
- Bet on These 3 High-Yield Stocks as Natural Gas Demand Grows
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
